This article is more than 5 years old. Information may no longer be current.

Vanderbilt dialysis clinic to begin using Nephros hemodiafiltration system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nephros Inc. said it has signed an agreement to enable a Vanderbilt Dialysis Clinic to offer hemodiafiltration (HDF) to patients. The agreement provides Vanderbilt with the Company’s OLpür H2H Hemodiafiltration System, dialysis supplies and service support to facilitate HDF treatment. The system is the only FDA 510(k) cleared medical device that enables nephrologists to provide HDF treatment to patients with ESRD.

Vanderbilt will be able to begin transferring selected and qualified patients over to HDF therapy in the next few months, Nephros said. These efforts will be lead by Dr. Jamie P. Dwyer, Associate Professor of Medicine in the Nephrology and Hypertension Division at Vanderbilt University School of Medicine and Co-Director of the Vanderbilt Nephrology Trials Center. Dr. Dwyer currently serves as Medical Director of the Vanderbilt Dialysis Clinic chosen to offer HDF treatment.